BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, LLC today announced the launch of Escitalopram Oxalate Oral Solution in 5 mg/5 mL strength, the first generic in liquid form on the market.

March 23, 2009 — Escitalopram oxalate (Lexapro, Forest Laboratories, Inc) has been approved by the US Food and Drug Administration (FDA) for the acute and maintenance treatment of major depressive ...

August 10, 2007 — The US Food and Drug Administration (FDA) has approved first-time generic formulations for dantrolene sodium injectable 20 mg/vial for the management of malignant hyperthermia; ...

NEW YORK, December 10 – Forest Laboratories, Inc. (NYSE: FRX) announced today the results of a clinical study, which showed that Lexapro TM (escitalopram oxalate) is as effective and well tolerated as ...

The FDA has approved Lexapro (escitalopram oxalate, from Forest Laboratories) for the acute and maintenance treatment of major depressive disorder (MDD) in adolescents 12–17 years of age. This ...

Mar. 21 -- FRIDAY, March 20 (HealthDay News) -- The Forest Laboratories antidepressant Lexapro (escitalopram oxalate) has been approved to treat major depressive disorder (MDD) in people aged 12 to 17 ...

Please provide your email address to receive an email when new articles are posted on . Drugmaker Lupin Pharmaceuticals Inc. announced today that the company has ...

Amneal announced the launch of Escitalopram oxalate oral solution 5mg/5mL, the generic version in liquid form of Forest Laboratories‘ Lexapro oral solution. Lexapro is a selective serotonin reuptake ...

BRIDGEWATER, N.J. — Amneal Pharmaceuticals has launched a generic version of an antidepressant made by Forest Labs. The drug maker announced the launch of escitalopram oxalate oral solution in ...

NEW YORK, December 18 - Forest Laboratories, Inc. (NYSE:FRX) announced today that the U.S. Food and Drug Administration (FDA) has approved Lexapro (escitalopram oxalate), a selective serotonin ...

Escitalopram is indicated for the treatment of major depressive disorder. This tentative approval is for the generic bioequivalent product to Lexapro (R), which is offered by Forest Laboratories, Inc.

NEW YORK, Sept. 5 -- Forest Laboratories and H. Lundbeck A/S of Denmark said today that the U.S. Court of Appeals for the Federal Circuit has affirmed a July 13, 2006 decision by the U.S. District ...